These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 30675299)

  • 1. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.
    Liu S; Kong P; Wang X; Yang L; Jiang C; He W; Quan Q; Huang J; Xie Q; Xia X; Zhang B; Xia L
    Oncol Lett; 2019 Feb; 17(2):2335-2343. PubMed ID: 30675299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.
    Kong P; Wang J; Song Z; Liu S; He W; Jiang C; Xie Q; Yang L; Xia X; Xia L
    J Cancer; 2019; 10(7):1745-1754. PubMed ID: 31205530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes.
    Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM
    Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment.
    Zhang Y; Sun Z; Mao X; Wu H; Luo F; Wu X; Zhou L; Qin J; Zhao L; Bai C
    Oncotarget; 2017 Oct; 8(49):85526-85536. PubMed ID: 29156738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
    Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
    Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance.
    Xin H; Zhou C; Wang G; Liu Y; Zhang J; Liu Y; Li B; Zhang J; Su M; Li Z; Wang G
    Heliyon; 2023 Feb; 9(2):e13048. PubMed ID: 36814622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
    Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
    Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance.
    Feng YC; Ji WL; Yue N; Huang YC; Ma XM
    Cancer Manag Res; 2018; 10():105-113. PubMed ID: 29403308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.
    Wang B; Li F; Guo L; Lu S; Ma J; Ma Y; Meng Y; Wang J; Zhou X; Fu W
    World J Surg Oncol; 2020 Aug; 18(1):196. PubMed ID: 32767974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
    Noh BJ; Kwak JY; Eom DW
    BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis.
    Mamat Yusof MN; Chew KT; Hafizz AMHA; Abd Azman SH; Ab Razak WS; Hamizan MR; Kampan NC; Shafiee MN
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes.
    Kim JK; Chen CT; Keshinro A; Khan A; Firat C; Vanderbilt C; Segal N; Stadler Z; Shia J; Balachandran VP; Weiser MR
    Oncoimmunology; 2022; 11(1):2054757. PubMed ID: 35481287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD169
    Saito Y; Fujiwara Y; Miyamoto Y; Ohnishi K; Nakashima Y; Tabata Y; Baba H; Komohara Y
    Cancer Med; 2023 May; 12(9):10199-10211. PubMed ID: 36846928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid-type poorly differentiated adenocarcinoma of the stomach: A characteristic morphology reveals a distinctive immunoregulatory tumor microenvironment.
    Kawatoko S; Kohashi K; Torisu T; Sasaki T; Umekita S; Oki E; Nakamura M; Kitazono T; Oda Y
    Pathol Res Pract; 2022 Oct; 238():154124. PubMed ID: 36137397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
    Özcan D; Lade-Keller J; Tramm T
    Pathol Res Pract; 2021 Oct; 226():153606. PubMed ID: 34530255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
    Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
    Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients.
    Liu SS; Yang YZ; Jiang C; Quan Q; Xie QK; Wang XP; He WZ; Rong YM; Chen P; Yang Q; Yang L; Zhang B; Xia XJ; Kong PF; Xia LP
    J Transl Med; 2018 Jul; 16(1):195. PubMed ID: 30005666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.